L3VLUP
ProSign in

ABOS · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ABOSGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ABOS
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterABOSGILD
Q3 2020none listed holders, n.a.25 holders, $14.2bn
Q4 2020none listed holders, n.a.27 holders, $13.4bn
Q1 2021none listed holders, n.a.24 holders, $14.5bn
Q2 2021none listed holders, n.a.18 holders, $14.9bn
Q3 20212 holders, $12m20 holders, $16.4bn
Q4 20212 holders, $5.7m20 holders, $16.8bn
Q1 20222 holders, $3.4m28 holders, $13.2bn
Q2 20222 holders, $3.7m26 holders, $13.6bn
Q3 20222 holders, $8.6m24 holders, $13.3bn
Q4 20222 holders, $2.5m32 holders, $21.1bn
Q1 20231 holders, $1.7m27 holders, $21.8bn
Q2 2023none listed holders, n.a.24 holders, $20.7bn
Q3 20231 holders, $2.2m24 holders, $20.0bn
Q4 20231 holders, $2.2m22 holders, $21.5bn
Q1 20241 holders, $2.3m30 holders, $20.3bn
Q2 2024none listed holders, n.a.28 holders, $18.5bn
Q3 2024none listed holders, n.a.29 holders, $24.2bn
Q4 2024none listed holders, n.a.28 holders, $25.9bn
Q1 2025none listed holders, n.a.33 holders, $32.0bn
Q2 2025none listed holders, n.a.27 holders, $30.9bn
Q3 2025none listed holders, n.a.23 holders, $29.4bn
Q4 2025none listed holders, n.a.25 holders, $34.3bn
Q1 2026none listed holders, n.a.25 holders, $38.5bn
Q2 2026none listed holders, n.a.26 holders, $34.2bn
ABOS

Acumen Pharmaceuticals Inc

Holders
0
Reported value
$0
Buyers
4
Sellers
8

Breadth -4 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
25
Reported value
$34.3bn
Buyers
18
Sellers
19

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2025

Among the 25 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only ABOS (0)

None.

Only GILD (25)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →